Psyched Wellness increases its bought deal offering from CAD$3 million to CAD$5.5 million.
Articles
Washington Lawmakers Approve Marijuana Homegrow Bill In Committee
A bill to allow marijuana homegrow in Washington State cleared its first legislative hurdle Friday morning, passing out of the House Commerce and Gaming Committee on a 7–2 vote with a “do pass” recommendation.
Mind Cure Health Inc. Announces an Increase to Previously Announced Bought Deal Public Offering
Mind Cure has upsized its bought deal financing by DOUBLE to CAD$20 million.
Albert Labs inks LOI to undergo reverse takeover of ME Resource in move to expand access to psychedelics
Albert Labs, a privately held psychedelic drug developer, signed a letter of intent (LOI) on January 5 to be acquired by ME Resource Corp (CSE:MEC) (OTC:MEEXF), the latter company announced.
Psyched Wellness Announces C$3M Bought Deal Private Placement Led by Canaccord Genuity
Psyched Wellness announces a CAD$3 million bought deal with units priced at CAD$0.31.
Numinus Announces Listing of New Warrants
Numinus announces the listing of its latest series of warrants for public trading, under the symbol "NUMI.WS". Warrants have an exercise price of CAD$0.90 and are valid until December 29, 2022.
Beckley Foundation: The Major Psychedelics Non-Profit Across The Pond
The UK-based Beckley Foundation is a psychedelics non-profit founded over 20 years ago that is having an increasing impact on the Psychedelics Revolution.
The first-ever psychedelics ETF will launch next week, backed by a Canadian fund manager
The first-ever psychedelics ETF will begin trading on the Canadian NEO exchange next Wednesday, giving investors exposure to publicly-traded companies focused on the development of therapeutic solutions that utilize psychedelics.
Illinois Awards $31.5 Million In Marijuana-Funded Grants To Repair Communities Harmed By Drug War
Illinois officials announced on Thursday that the state is distributing $31.5 million in grants funded by marijuana tax revenue to communities that have been disproportionately impacted by the war on drugs.
New clinical trial to explore DMT as treatment for substance use disorders
The Canadian R&D company Entheon Biomedical has set out to investigate the therapeutic use of the psychedelic dimethyltryptamine (DMT) in treating addiction disorders. Specifically, the company has commissioned a clinical trial investigating the safety and efficacy of using intravenous DMT.
Congressman Files First Federal Marijuana Reform Bill Of 2021
The first marijuana reform bill of the new Congress was introduced this week.
MindMed Announces the Start of the First-Ever Clinical Trial Combining MDMA and LSD
MindMed begins the first Phase 1 clinical trial testing the safety and tolerance of MDMA and LSD in combination.
Unique magic mushroom microdosing study to begin in Australia
A novel Australian trial is set to investigate the popular yet still deeply unproven practice of microdosing psychedelics.
Top Penny Stocks To Watch For 2021 If You’re Following Mushroom Stocks
Whether you’ve traded for decades or just opened an account, the market attracts you for a reason.
France Asks for Citizen Input on Cannabis Legalization & Related Policies
France has launched a public consultation about cannabis legalization asking citizens about their views on cannabis and what government policies people would prefer, France24 reports.